iMMagine-3

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

May 13, 2024 → Oct 9, 2026

Cited window

Sep 27, 2024 → Oct 9, 2026

Retrieved

Oct 18, 2026

Title

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma

Registry

NCT06413498

Study IDs

KT-US-679-0788 · 2024-511188-26 (European Medicines Agency) · jRCT2043240170 (Japan Registry of Clinical Trials)

Sponsor

Kite, A Gilead Company

Collaborators

Arcellx, Inc.

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

452 actual

Start

2024-08-23 actual

Primary completion

2028-07 estimated

Primary endpoint

Progression-Free Survival (PFS)

Interventions

8 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –Out of scope: 4 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
• –361 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The commentary comes from 21 sources reviewed for this edition. Repeated presentations and posts may describe the same evidence or speakers; source counts do not measure the number of independent clinicians supporting a view.
• –Searches emphasized study identifiers and drug-name variants. Unnamed discussions, transcription variants and relevant treatment-decision discussions without a trial reference may be missing. Some discussions centered on other CAR-T products or earlier anito-cel studies were excluded, and some passages were not fully assessed.
• –Posts predating trial registration were excluded when they did not name the trial. Consequently, this edition may miss earlier views on the same relapsed/refractory treatment question.
• –No protocol or results publication for NCT06413498 was available among the sources reviewed. Earlier-phase efficacy and safety observations must not be read as results of the randomized Phase 3 trial. No exact anitocabtagene autoleucel label was available to establish its current regulatory status.
• –Different presentations describe different follow-up periods, evaluable populations and data updates. Response, MRD, outpatient-treatment and safety figures are not pooled or treated as interchangeable. Absence of an observed delayed event does not establish absence of risk.
• –Bhella called a single-arm study requiring at least three prior lines phase 2 IMAGINE-3. That wording is preserved as her account, not adopted as the design of the registered Phase 3 study. Her description of no serious CRS is not reconciled with Kaur's report of fatal CRS in iMMagine-1.
• –Two videos rely on existing transcripts, which leaves additional uncertainty about wording and speaker identity. Some passages also leave time units, response-category abbreviations, regimen boundaries or bridging proportions unclear; no unstated correction is assumed. One additional CRS passage does not establish an overall incidence clearly enough to report one.
• –Some speakers and audience members cannot be identified. The unnamed X account's clinical role is unknown. Noopur Raje and Krina Patel are named in their sources, but independent documentation of their clinical roles is unavailable here. Audience experiences are kept separate from clinician assessments and formal trial outcomes.
• –Some potentially relevant discussion of worldwide access and alternative in-vivo or dual-target CAR-T approaches is incomplete. Missing prior-treatment details and safety qualifications prevent a complete comparison of those alternatives.
• –A first-line efficacy and tolerability discussion involving an unidentified treatment is not used as evidence for the relapsed/refractory decision. The answer to the MRD quality-of-life question uses DARA-VRD transplant/non-transplant studies only as context for that exchange, not as RRMM or iMMagine-3 evidence. Other frontline quadruplet examples are likewise not used to imply effects in iMMagine-3.
• –Approval forecasts, expected decision dates, funding descriptions and local access statements reflect the speaker's time and jurisdiction. They do not establish current approval, availability or a subsequent change in clinical opinion.
• –Parts of Freeman's own construct explanation and Phase 1 durability discussion, as well as portions of future sequencing, combination-treatment and daratumumab-positioning discussions, are not fully represented. Other speakers' accounts cannot substitute for those views, so this edition may miss additional rationales, qualifications or development questions.

How reports are built and checked: Methods.

Last checked for new commentary Oct 19, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.